Gastric pH and Therapeutic Responses to Exsomeprazole in Patients With Functional Dyspepsia: Potential Clinical Implications

[1]  N. Talley,et al.  Functional dyspepsia. , 2017, Australian prescriber.

[2]  J. Qian,et al.  Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: A five‐way crossover study , 2013, Journal of gastroenterology and hepatology.

[3]  Baoping Yu,et al.  Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease. , 2013, World journal of gastroenterology.

[4]  T. Bishop,et al.  Proton Pump Inhibitor Use in the U.S. Ambulatory Setting, 2002–2009 , 2013, PloS one.

[5]  B. Lacy.  Functional Dyspepsia and Gastroparesis: One Disease or Two? , 2012, The American Journal of Gastroenterology.

[6]  P. Bytzer,et al.  Partial symptom‐response to proton pump inhibitors in patients with non‐erosive reflux disease or reflux oesophagitis – a post hoc analysis of 5796 patients , 2012, Alimentary pharmacology & therapeutics.

[7]  A. Bredenoord,et al.  PPI therapy is equally effective in well‐defined non‐erosive reflux disease and in reflux esophagitis: a meta‐analysis , 2012, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[8]  P. Moayyedi,et al.  Review article: current treatment options and management of functional dyspepsia , 2012, Alimentary pharmacology & therapeutics.

[9]  P. Wahlqvist,et al.  Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole – results from the STARS II study , 2011, Alimentary pharmacology & therapeutics.

[10]  E. Christensen,et al.  Randomised clinical trial: identification of responders to short‐term treatment with esomeprazole for dyspepsia in primary care – a randomised, placebo‐controlled study , 2011, Alimentary pharmacology & therapeutics.

[11]  K. Iwakiri,et al.  Pathophysiology of functional dyspepsia. , 2011, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[12]  R. Brun,et al.  Review: Functional dyspepsia , 2010, Therapeutic advances in gastroenterology.

[13]  C. Reimer,et al.  Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. , 2009, Gastroenterology.

[14]  Vic Velanovich,et al.  Esomeprazole: a proton pump inhibitor , 2009, Expert review of gastroenterology & hepatology.

[15]  L. Russo,et al.  Correlation between oesophageal acid exposure and dyspeptic symptoms in patients with nonerosive reflux disease , 2008, European journal of gastroenterology & hepatology.

[16]  K. Ho,et al.  In-Practice Predictors of Response to Proton Pump Inhibitor Therapy in Primary Care Patients With Dyspepsia in an Asian Population , 2008, Journal of clinical gastroenterology.

[17]  G. Keating,et al.  Esomeprazole , 2012, Drugs.

[18]  K. Lauritsen,et al.  One‐week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks’ treatment with esomeprazole: a randomized, placebo‐controlled study , 2007, Alimentary pharmacology & therapeutics.

[19]  K. Lauritsen,et al.  Randomized‐controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1‐week trial of acid suppression predict symptom response? , 2007, Alimentary pharmacology & therapeutics.

[20]  S. Roman,et al.  Correlation between gastric pH and gastro‐oesophageal reflux contents: ambulatory pH‐impedance monitoring results , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[21]  D. Armstrong,et al.  Esomeprazole 40 mg Once a Day in Patients with Functional Dyspepsia: The Randomized, Placebo-Controlled “ENTER” Trial , 2006, The American Journal of Gastroenterology.

[22]  D. Forman,et al.  Eradication of Helicobacter pylori for non-ulcer dyspepsia. , 2006, The Cochrane database of systematic reviews.

[23]  P. Moayyedi,et al.  American gastroenterological association technical review on the evaluation of dyspepsia. , 2005, Gastroenterology.

[24]  D. Johnson,et al.  A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro‐oesophageal reflux disease , 2005, Alimentary pharmacology & therapeutics.

[25]  袁孟彪,et al.  Functional dyspepsia , 2005 .

[26]  M. Robinson.  Dyspepsia: challenges in diagnosis and selection of treatment. , 2001, Clinical therapeutics.

[27]  M. Camilleri,et al.  Functional gastroduodenal disorders , 1999, Gut.